Financials in USD. Standardized financial statements.
A compact view of how Immunovia AB (publ) turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $683,281 | $931,000 | $1.57M | $1.15M | $844,000 | $362,000 | $356,000 | $333,000 | $148,963 | $177,284 |
| Revenue Growth? | -26.6% | -40.9% | +37.6% | +35.7% | +133.1% | +1.7% | +6.9% | +123.5% | -16.0% | 0.0% |
| Cost of Revenue? | $79.99M | $0 | $6.68M | $4.21M | -$14.97M | -$40.02M | -$26.72M | -$25.05M | -$24.04M | -$24.29M |
| Gross Profit? | -$79.30M | $931,000 | -$5.11M | -$3.07M | $15.81M | $40.38M | $27.07M | $25.39M | $24.19M | $24.47M |
| Gross Margin? | -11606.4% | +100.0% | -324.3% | -267.8% | +1873.6% | +11155.2% | +7604.5% | +7623.1% | +16238.8% | +13802.7% |
| Operating Expenses? | $0 | $110.34M | $291.35M | $188.14M | $182.55M | $175.06M | $141.42M | $113.62M | $69.77M | $39.48M |
| Operating Income? | -$79.30M | -$109.41M | -$296.46M | -$191.15M | -$166.63M | -$134.34M | -$114.25M | -$87.71M | -$45.52M | -$14.98M |
| EBITDA? | -$76.99M | -$61.27M | -$148.46M | -$141.58M | -$135.47M | -$134.85M | -$104.75M | -$85.45M | -$43.96M | -$14.17M |
| Income Before Tax | -$145.55M | -$76.54M | -$309.44M | -$168.09M | -$155.97M | -$146.03M | -$114.52M | -$86.53M | -$45.23M | -$14.72M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $4,000 | $7,000 | -$14,940.229 | -$907.356 |
| Net Income? | -$145.55M | -$76.54M | -$309.44M | -$168.09M | -$155.97M | -$146.03M | -$114.52M | -$86.54M | -$45.23M | -$14.72M |
| EPS? | $-0.42 | $-0.93 | $-7.95 | $-6.89 | $-6.40 | $-6.35 | $-5.43 | $-4.33 | $-2.48 | $-0.91 |
| Diluted EPS? | $-0.42 | $-0.93 | $-7.95 | $-6.89 | $-6.40 | $-6.35 | $-5.43 | $-4.33 | $-2.48 | $-0.91 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality